Special Issue

Molecular Mechanisms of Breast Cancer Treatment-Related Side Effects and Precision Interventions

Message from the Guest Editor

More aggressive and effective treatments, particularly in combination, have improved overall survival in breast cancer patients. However, they come at a steep price: debilitating side effects that negatively impact patients' quality of life. Many patients endure a grueling, acute. and prolonged battle against fatigue, cognitive impairment, chronic pain, and overall ill health. To improve the clinical outcomes of breast cancer, we need to preserve the quality of life of cancer survivors in addition to developing new treatments. This requires a radical shift from one-size-fits-all approaches to a new era of precision medicine and interventions. By pinpointing the specific molecular mechanisms of side effects, we can develop highly targeted precision interventions. The future of cancer care will tailor more effective treatments to the individual using pharmacogenomics and biomarker-guided therapies and interventions. The goal is to optimize treatments, minimize side effects, and improve clinical outcomes for breast cancer survivors.

- breast cancer
- treatment-related side effects
- biomarker
- precision interventions

Guest Editor

Prof. Dr. Jennifer Hu

Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL 33136. USA

Deadline for manuscript submissions

26 May 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/248853

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

